ATE97815T1 - Kombiniertes hepatitis a- und b-vakzin mit adjuvans. - Google Patents

Kombiniertes hepatitis a- und b-vakzin mit adjuvans.

Info

Publication number
ATE97815T1
ATE97815T1 AT89107762T AT89107762T ATE97815T1 AT E97815 T1 ATE97815 T1 AT E97815T1 AT 89107762 T AT89107762 T AT 89107762T AT 89107762 T AT89107762 T AT 89107762T AT E97815 T1 ATE97815 T1 AT E97815T1
Authority
AT
Austria
Prior art keywords
hepatitis
vaccine
virus
adjuvants
antigens
Prior art date
Application number
AT89107762T
Other languages
English (en)
Inventor
Syoji Kuzuhara
Koichi Odo
Kyosuke Mizuno
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14441535&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE97815(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of ATE97815T1 publication Critical patent/ATE97815T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT89107762T 1988-04-28 1989-04-28 Kombiniertes hepatitis a- und b-vakzin mit adjuvans. ATE97815T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63106748A JPH085804B2 (ja) 1988-04-28 1988-04-28 Ａ型及びｂ型肝炎混合アジュバントワクチン
EP89107762A EP0339667B1 (de) 1988-04-28 1989-04-28 Kombiniertes Hepatitis A- und B-Vakzin mit Adjuvans

Publications (1)

Publication Number Publication Date
ATE97815T1 true ATE97815T1 (de) 1993-12-15

Family

ID=14441535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89107762T ATE97815T1 (de) 1988-04-28 1989-04-28 Kombiniertes hepatitis a- und b-vakzin mit adjuvans.

Country Status (6)

Country Link
US (1) US5151023A (de)
EP (1) EP0339667B1 (de)
JP (1) JPH085804B2 (de)
AT (1) ATE97815T1 (de)
DE (1) DE68911019T2 (de)
ES (1) ES2059612T3 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751513B2 (ja) * 1988-04-28 1995-06-05 国立予防衛生研究所長 Ａ型肝炎ワクチン
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
SG48365A1 (en) * 1992-05-23 1998-04-17 Smithkline Beecham Biolog Combined vaccines comprising hepatitis b surface antigen and other antigens
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5728385A (en) * 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US7008790B1 (en) * 1993-08-12 2006-03-07 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
FR2730935A1 (fr) * 1994-12-21 1996-08-30 Vacsyn Sa Vaccin presentant une immunogenicite accrue
US6153202A (en) * 1998-03-06 2000-11-28 The United States Of America As Represented By The Secretary Of Agriculture In ovo methods for utilizing live Edwardsiella ictaluri against enteric septicemia in channel catfish
US6019981A (en) * 1998-03-06 2000-02-01 The United States Of America As Represented By The Secretary Of Agriculture Modified live Edwardsiella ictaluri against enteric septicemia in channel catfish
NZ506602A (en) 1998-03-09 2003-02-28 Smithkline Beecham Biolog S Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
US20030022304A1 (en) * 1998-03-25 2003-01-30 Smithkline Beecham Biologicals, S.A. Vaccine composition
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6379677B1 (en) * 2000-02-25 2002-04-30 The United States Of America As Represented By The Secretary Of The Department Of Agriculture Streptococcus iniae vaccine
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
US7033500B2 (en) 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US6825027B2 (en) * 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
GB0224688D0 (en) * 2002-10-23 2002-12-04 Glaxosmithkline Biolog Sa Method
CN1513555A (zh) * 2003-07-31 2004-07-21 长春生物制品研究所 甲-乙型肝炎联合疫苗及其冻干制剂
WO2005117965A1 (en) 2004-06-04 2005-12-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing immunogenic conjugates
CN101085347B (zh) * 2007-06-15 2010-05-19 东南大学 甲型肝炎-乙型肝炎-戊型肝炎联合疫苗
WO2013049535A2 (en) 2011-09-30 2013-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Influenza vaccine
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
RU2638298C1 (ru) 2014-02-05 2017-12-13 Абб Текнолоджи Лтд. Сердечник конденсатора
WO2018067582A2 (en) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide immunogens and their use
US11202824B2 (en) 2016-10-31 2021-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
US11235056B2 (en) 2017-03-24 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of HIV-1 gp120 and their use
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
US12053519B2 (en) 2018-09-23 2024-08-06 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
EP3870703A1 (de) 2018-10-22 2021-09-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Rekombinantes gp120-protein mit v1-schleifendeletion
US12210017B2 (en) 2020-01-08 2025-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptides representing epitopes from filoviruses
WO2023015186A1 (en) 2021-08-03 2023-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
US20250197455A1 (en) 2022-03-27 2025-06-19 TThe United States of America, as represented by the Secretary, Department of Health and Human Servi Base-covered hiv-1 envelope ectodomains and their use
WO2024249626A1 (en) 2023-05-30 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 envelope triple tandem trimers and their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100267A (en) * 1975-10-01 1978-07-11 Ortho Diagnostics Inc. Method of detecting hepatitis B core antigen and antibody
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US4741901A (en) * 1981-12-03 1988-05-03 Genentech, Inc. Preparation of polypeptides in vertebrate cell culture
US4620978A (en) * 1982-04-07 1986-11-04 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis A virus purified and triply cloned
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4657761A (en) * 1985-06-05 1987-04-14 Pinto Cesar M Polyvalent non-specific immuno-stimulating vaccine and method
US4783407A (en) * 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
ZA872532B (en) * 1986-04-21 1987-11-25 Akzo Nv Combined vaccine

Also Published As

Publication number Publication date
DE68911019D1 (de) 1994-01-13
EP0339667A3 (en) 1990-06-13
US5151023A (en) 1992-09-29
JPH01279842A (ja) 1989-11-10
EP0339667B1 (de) 1993-12-01
DE68911019T2 (de) 1994-05-19
EP0339667A2 (de) 1989-11-02
JPH085804B2 (ja) 1996-01-24
ES2059612T3 (es) 1994-11-16

Similar Documents

Publication Publication Date Title
ATE97815T1 (de) Kombiniertes hepatitis a- und b-vakzin mit adjuvans.
ATE74012T1 (de) Lyophilisierte hepatitis-b-vakzine.
AU572162B2 (en) Hepatitis b vaccine
RU94046145A (ru) Комбинированные вакцины, содержащие поверхностный антиген гепатита в и другие антигены, способ их получения, способ предупреждения инфекций гепатита в
DK0527815T3 (da) Hepatitis C-virus-epitop
DK0522030T3 (da) Hepatitis B-vaccine
EP1018344A3 (de) HLA-reduzierte CTL-Epitope gegen Hepatite B-Virus
DE68928119D1 (de) Non-A, non-B-Hepatitisvirus-Antigenpeptid
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
SE8205313D0 (sv) Antigen-proteinkomplex for blockering av allergiska reaktioner samt sett for framstellning derav
LU91593I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine, d'antigène de surface recombinant du virus de l'hépatite B (protéine S), de virus poliomyélitique inactivé type1, type 2 et type 3 et de polyoside d'Haemophilus influenzae type b (Infanrix Hexa)
ATE176157T1 (de) Pädiatrische kombinationsvakzine mit verbesserter immunogenizität jeder vakzine komponente
RU93048161A (ru) Комбинированная педиатрическая вакцина с усиленной иммуногенностью каждого вакционного компонента
FI880802A7 (fi) Hepatitis B-viruspinta-antigeenin esi-S-alueen T- ja B-soluepitoopit.
BR9106601A (pt) Adjustante de vacina e processo de obter aumento da resposta imunologica a um antigeno em um ser humano ou animal
DK0533294T3 (da) Kyllingeanæmiagensvaccine.
EP0339668A3 (de) Hepatitis-A-Virus aufgebautes Antigen
AU7909391A (en) Epitopes of the pre-s region of hepatitis b virus surface antigen
SE8604588D0 (sv) Antikroppspreparation riktad mot paratyreoidea, dess framstellning och anvendning

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time